Experts believe the price of Aptos (APT) could drop to $8.23 by May 20.
Analysts predict Injective's (INJ) price decline to $21.68 by May 23.
Milei Moneda ($MEDA) excites investors with its impressive presale performance.
Despite the overall bullish market trend, Aptos (APT) and Injective (INJ) have struggled to break through their resistance levels, facing further price declines. Meanwhile, Milei Moneda ($MEDA) has surpassed expectations in its ongoing public presale, setting it up to outperform experts' projections as it prepares to list on Uniswap.
But the main question is, how is $MEDA outperforming these top crypto coins? Read on to find out!
The annual price chart reveals a significant decline of over 34% for Aptos, attributed to setbacks in the overall market during the previous months. Surprisingly, this price decline coincided with a groundbreaking partnership between Aptos Labs and the tech giant Google Cloud to revolutionize gaming by integrating Web3 technology.
Although the recent introduction of APT tokens worth a substantial $351 million into circulation sparked optimism, Aptos has continued to drop. In the past week, its price failed to break its resistance level, while Aptos's crypto market cap also fell by nearly 2% despite the overall surge in the market.
With technical indicators still pointing to bearish market conditions, crypto analysts are anticipating further price decreases for Aptos in the near future. Based on their analysis, they forecast APT could decline to as low as $8.23 by May 20 unless positive catalysts emerge to shift the current market momentum.
Injective has experienced remarkable growth over the past year. However, due to the overall market setback, the price of Injective has seen a decline of more than 33% in the last 30 days. This downtrend has been further exacerbated in the past week, as the daily trading volume of Injective also dropped by over 20%.
In an attempt to boost the price amid the broader market surge, Injective implemented deflationary measures, burning 10,000 INJ tokens on April 24. However, these efforts have not immediately translated into a price recovery, as buyers are hesitant to enter the market until INJ surpasses its resistance level.
With the Relative Strength Index (RSI) still below the 50 mean level, which indicates a subdued market sentiment with lower highs being recorded, market experts believe the price of Injective could continue to decline. Consequently, they predict the price of INJ could drop to $21.68 by May 23.
Milei Moneda's meteoric rise in popularity and strong performance in its presale indicate that it is on track to surpass expert projections. The overwhelming demand in Stage 1 of the presale, which sold out completely, is a testament to the growing confidence and enthusiasm surrounding Milei Moneda.
Investor interest in Milei Moneda continues to soar, with over 65 million tokens already sold. This surge in demand solidifies its position as one of the market's top-performing altcoins. Currently in Stage 2 of its presale with an altcoin price of $0.0125, Milei Moneda presents an enticing opportunity for investors to acquire $MEDA tokens and capitalize on its immense potential.
Excitement is building as Milei Moneda prepares for its official listing on Uniswap. As a result, presale investors can expect a remarkable 60% ROI when the $MEDA launches at $0.020 per token on May 21, 2024. What's more, industry experts are anticipating a 100x surge when the Milei Moneda token starts trading on the best crypto exchange platforms.
While Aptos and Injective tokens have struggled to break resistance despite an overall bullish market environment, Milei Moneda has exceeded expectations through robust investor demand in its public presale. The emerging memecoin appears poised to outshine crypto experts' projections with its imminent launch on Uniswap.
Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp
_____________
Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.